Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Working Capital Changes (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Working Capital Changes for 16 consecutive years, with -$236000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 89.75% to -$236000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$744000.0 through Dec 2025, down 43.08% year-over-year, with the annual reading at $10945.0 for FY2025, 102.1% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$236000.0 at Gyre Therapeutics, up from -$603000.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $5.5 million in Q1 2025, with the low at -$5.4 million in Q2 2025.
  • Average Other Working Capital Changes over 5 years is -$119336.0, with a median of $569.0 recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 12418.48% in 2024, while the deepest fall reached 2802.15% in 2024.
  • Over 5 years, Other Working Capital Changes stood at -$623000.0 in 2021, then surged by 68.06% to -$199000.0 in 2022, then soared by 322.61% to $443000.0 in 2023, then crashed by 619.86% to -$2.3 million in 2024, then surged by 89.75% to -$236000.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$236000.0, -$603000.0, and -$5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.